A review of approaches for the management of specialty pharmaceuticals in the United States.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2014 AND VI 32 AND IP 11
Results: 12
1
2
Through a Glass Darkly: Economics and Personalised Medicine.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1055, doi. 10.1007/s40273-014-0190-6
- By:
- Publication type:
- Article
3
Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1063, doi. 10.1007/s40273-014-0191-5
- By:
- Publication type:
- Article
4
Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1079, doi. 10.1007/s40273-014-0192-4
- By:
- Publication type:
- Article
5
The Health Economics of Bladder Cancer: An Updated Review of the Published Literature.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1093, doi. 10.1007/s40273-014-0194-2
- By:
- Publication type:
- Article
6
Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best-Best Discrete Choice Experiment.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1115, doi. 10.1007/s40273-014-0188-0
- By:
- Publication type:
- Article
7
The Problem of Embedded Decision Nodes in Cost-Effectiveness Decision Trees.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1141, doi. 10.1007/s40273-014-0195-1
- By:
- Publication type:
- Article
8
Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer's Disease.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1129, doi. 10.1007/s40273-014-0203-5
- By:
- Publication type:
- Article
9
Some Inconsistencies in NICE's Consideration of Social Values.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1043, doi. 10.1007/s40273-014-0204-4
- By:
- Publication type:
- Article
10
NICE, Social Values, and Balancing Objectivity and Equity.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1039, doi. 10.1007/s40273-014-0220-4
- By:
- Publication type:
- Article
11
Should Off-Label Drugs Be Included as Comparators in Pharmacoeconomic Studies?
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1035, doi. 10.1007/s40273-014-0222-2
- By:
- Publication type:
- Article
12
A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 11, p. 1105, doi. 10.1007/s40273-014-0196-0
- By:
- Publication type:
- Article